Pretreatments of mice with patient-derived xenograft tumours with TGFBR1 inhibitor galunisertib/LY2157299 led to reduced tumour growth and ascites development [24], suggesting potential as a maintenance therapy to limit recurrence. Here, TGFBR1 is linked to neoplasm.